Literature DB >> 24830890

Addressing matrix effects in ligand-binding assays through the use of new reagents and technology.

Shannon D Chilewski1, Johanna R Mora, Carol Gleason, Binodh DeSilva.   

Abstract

BACKGROUND: Ligand-binding assays (LBAs) used in the quantification of biotherapeutics for pharmacokinetic determinations rely on interactions between reagents (antibodies or target molecule) and the biotherapeutic. Most LBAs do not employ an analyte extraction procedure and are susceptible to matrix interference. Here, we present a case study on the development of a LBA for the quantification of a PEGylated domain antibody where matrix interference was observed. The assay used to support the single ascending dose study was a plate-based electrochemiluminescent assay with a lower limit of quantification of 80 ng/mL. To meet sensitivity requirements of future studies, new reagents and the Gyrolab™ Workstation were evaluated.
RESULTS: Assay sensitivity improved nearly threefold in the final method utilizing new antibody reagents, a buffer containing blockers to human anti-animal antibodies, and the Gyrolab Workstation.
CONCLUSION: Experimental data indicate that all factors changed played a role in overcoming matrix effects.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24830890     DOI: 10.4155/bio.14.75

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  1 in total

1.  Singlicate Ligand Binding Assay Using an Automated Microfluidic System: a Clinical Case Study.

Authors:  Hao Jiang; Alex Kozhich; Jennifer Cummings; Janice Gambardella; Frank Zambito; Craig Titsch; Jonathan Haulenbeek; Kelli Phillips; Ross Fergus; Heather Myler
Journal:  AAPS J       Date:  2017-06-06       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.